InvestorNewsBreaks – Cognos Therapeutics Corp. Signs Agreement to Work with Maxim Group LLC for Investment Banking, Financial Advisory Services

June 21, 2021 08:32:35

Cognos Therapeutics Corp., an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases, has signed a letter of engagement with Maxim Group LLC. According to the agreement, Maxim will provide financial advisory and investment banking services to Cognos; the services will also include support in identifying and evaluating merger and acquisition opportunities. “We are incredibly pleased to launch this relationship with Maxim,” said Cognos CEO Frank Adell in the press release. “We believe Maxim can assist us in pursuing strategic growth and in building long-term value for our shareholders. . . . Our goal is that this will further enable us to focus on our product, the Sinnais, a standalone, implantable smart pump. This closed-loop, MRI-compatible medical device is designed to deliver therapeutic drugs locally and metronomically to a desired area. Specifically, our focus is on delivering drugs into the neuro region. Sinnais has full wireless communication capability and compatibility with the cloud.”

To view the full press release, visit

About Cognos Therapeutics Inc.

Cognos Therapeutics is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases, including tumor-based brain and spinal cancers, degenerative cognition disorders such as Alzheimer’s and Parkinson’s disease, and cerebral trauma occurrences such as epilepsy and stroke, as well as other central nervous system afflictions. For more information about the company, visit

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.